Context Therapeutics: 22% confirmed ovarian cancer response
CT-202's U.S. investigational new drug application filing is on track by year-end 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Context Therapeutics Inc. reported third-quarter 2026 results and clinical updates for CTIM-76 and CT-202. In nine efficacy-evaluable patients with platinum-resistant ovarian cancer receiving biologically active weekly CTIM-76 doses, confirmed ORR was 22%, DCR was 56%, and median PFS was 5.6 months as of October 30, 2026. Seven of seven liver target lesions decreased across four patients. Grade ≥3 treatment-emergent adverse events occurred in 22 of 27 patients; cytokine release syndrome affected five of 27, all Grade 1 or 2. Escalation to 420 µg every three weeks began after the 280 µg dose-limiting toxicity assessment.
Cash and cash equivalents were $34.4 million at September 30, 2026, which Context expects to fund operations to early Q4 2027. Third-quarter net loss was $7.6 million, compared with $9.7 million in third-quarter 2025; research and development expense was $5.7 million versus $8.7 million. CTIM-76 Phase 1b expansion is expected in Q1 2027, with initial every-three-week efficacy data expected in Q2 2027. CT-202's first patient was dosed in September 2026; initial Phase 1a data are expected in 2H 2027.
Positive
- Minor pointCTIM-76: 22% confirmed ORR and 56% DCR in nine evaluable PROC patients.
Negative
- Minor pointGrade ≥3 treatment-emergent adverse events occurred in 22 of 27 patients.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $34.4 million
Research and development expenses: $5.7 million, versus $8.7 million
General and administrative expenses: $2.2 million, versus $1.9 million
+2 more
5 metrics
Cash and cash equivalents
$34.4 million
As of September 30, 2026
Research and development expenses
$5.7 million, versus $8.7 million
Third quarters of 2026 and 2025, respectively
General and administrative expenses
$2.2 million, versus $1.9 million
Third quarters of 2026 and 2025, respectively
Other income
$0.3 million, versus $0.9 million
Third quarters of 2026 and 2025, respectively
Net loss
$7.6 million, versus $9.7 million
Third quarters of 2026 and 2025, respectively
Key Terms
objective response rate, disease control rate, progression-free survival, dose-limiting toxicity, +1 more
5 terms
objective response rate medical
"the confirmed objective response rate (“ORR”) was 22%"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
disease control rate medical
"the disease control rate (“DCR”) was 56%"
The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.
progression-free survival medical
"median progression-free survival (“PFS”) of 5.6 months"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
dose-limiting toxicity medical
"The dose-limiting toxicity (“DLT”) evaluation period at 280 µg Q3W is complete"
Dose-limiting toxicity is a serious, treatment-related side effect observed in clinical trials that prevents researchers from safely increasing a drug’s dose. It matters to investors because these toxic effects set the maximum tolerated dose, influence whether a drug can reach levels that are effective, and therefore affect development timelines, costs, and the chance of regulatory approval — like a safety speed limit on how far a drug program can go.
cytokine release syndrome medical
"Cytokine release syndrome occurred in 5 of 27 patients"
An intense immune overreaction in which the body's defense system releases a large surge of signaling proteins, causing fever, low blood pressure, breathing trouble or organ stress; imagine the immune system's alarm going into overdrive and flooding the body with emergency responders. Investors care because this side effect can slow or block regulatory approval, increase clinical trial costs and liabilities, limit how widely a therapy can be used, and therefore affect a drug's market value and sales potential.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were CNTX's CTIM-76 results in PROC?
Among nine efficacy-evaluable PROC patients treated with biologically active weekly doses, CTIM-76 had a 22% confirmed ORR, a 56% DCR, and median PFS of 5.6 months as of October 30, 2026. The median PFS 95% confidence interval was 1.2–7.4 months.
How much cash did CNTX have, and how long did it expect to last?
CNTX had $34.4 million in cash and cash equivalents as of September 30, 2026, and expected it to fund operations to early Q4 2027. The company reported a Q3 2026 net loss of $7.6 million, compared with $9.7 million in Q3 2025.
Which Grade 3 or higher adverse events were most common in the CTIM-76 study?
Among 27 treated patients, the most common Grade ≥3 events included increased GGT in 37.0%, increased AST in 29.6%, increased ALT in 22.2%, increased lipase in 18.5%, and anemia in 14.8%.
What is CNTX's CT-202 development status?
The first patient was dosed in September 2026, and six trial sites were active in Australia. Context said its U.S. IND filing was on track by year-end 2026, with initial Phase 1a data expected in 2H 2027.
Does CTIM-76 have FDA Fast Track designation?
Yes. The FDA granted CTIM-76 Fast Track designation for patients with platinum-resistant ovarian cancer who have received all standard-of-care therapies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
$0.001 par value per share | ||||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On November 10, 2026, Context Therapeutics Inc. (the "Company") issued a press release announcing its third quarter 2026 operating and financial results and providing updates on its pipeline progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 8.01. Other Events.
On November 10, 2026, the Company updated its corporate presentation (the "Corporate Presentation"). A copy of the Corporate Presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by Context Therapeutics Inc., dated November 10, 2026 | |||||||
| 99.2 | Context Therapeutics Inc. Corporate Presentation — November 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 10, 2026 | Context Therapeutics Inc. | |||||||
| By: | /s/ Martin A. Lehr | |||||||
| Name: Martin A. Lehr | ||||||||
| Title: Chief Executive Officer | ||||||||
Exhibit 99.1
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR,
56% confirmed DCR, and median PFS of 5.6 months
56% confirmed DCR, and median PFS of 5.6 months
Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg
Phase 1b initiation expected in Q1 2027 and initial Q3W efficacy data in Q2 2027
Cash and cash equivalents of $34.4 million as of September 30, 2026 expected to fund operations to early Q4 2027
PHILADELPHIA, November 10, 2026 -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the third quarter ended September 30, 2026, and reported on recent and upcoming business highlights. The Company also reported longer-term follow-up from weekly (“QW”) dosing and initial safety from every-three-week (“Q3W”) dosing in the ongoing Phase 1 trial of CTIM-76, its Claudin 6 (“CLDN6”) x CD3 TCE.
Longer-term Phase 1 follow-up showed median progression-free survival (“PFS”) of 5.6 months at biologically active weekly doses of 140–280 µg. An emerging association between dose, cytokine and T cell activation, and tumor shrinkage is informing dose selection as the Company optimizes every-three-week dosing and advances toward Phase 1b at a dose of 280 µg or higher. CTIM-76 was generally well tolerated, supporting further Q3W dose escalation from 280 µg to 420 µg. Activity extended to liver metastases, which are typically difficult to treat with immunotherapy:1 all seven liver target lesions decreased in size, including two that disappeared completely. While preliminary, these efficacy, pharmacodynamic and tolerability findings support continued development of CTIM-76 and further evaluation of its potential as a best-in-class TCE for platinum-resistant ovarian cancer (“PROC”).
“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy,” said Martin Lehr, Chief Executive Officer of Context. “Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness,2 providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.3 We view the results
to date as an initial benchmark, with Phase 1b providing an opportunity to further define CTIM-76’s clinical potential.”
Recent Pipeline Progress and Upcoming Milestones of Prioritized Clinical Programs:
CTIM-76: CLDN6 x CD3 TCE
Context is evaluating CTIM-76 as a monotherapy in a Phase 1 trial in patients with CLDN6-positive PROC, testicular and endometrial cancers. The U.S. FDA has granted Fast Track designation to CTIM-76 for patients with PROC who have received all standard-of-care therapies.
Patients
•As of October 30, 2026, 27 patients with ovarian (n=20), testicular (n=4) and endometrial (n=3) cancer had received CTIM-76 in dose escalation cohorts, either QW at 22.5 to 560 µg (n=21) or Q3W at 280 µg (n=6).
•Fifteen patients with PROC were treated at biologically active doses, either 140 to 280 µg QW (n=9) or 280 µg Q3W (n=6). These patients had received a median of 6 prior lines of therapy (range, 3–16), and 12 (80%) had received a prior antibody-drug conjugate (“ADC”) therapy, including 5 (33%) who had received two or more ADCs.
Efficacy
•Among efficacy evaluable PROC patients treated QW at biologically active doses (n=9), the confirmed objective response rate (“ORR”) was 22% and the disease control rate (“DCR”) was 56%. Two patients (22%) achieved a confirmed partial response and 3 (33%) had stable disease.
•As of October 30, 2026, median PFS was 5.6 months (95% CI: 1.2–7.4 months) among efficacy-evaluable PROC patients treated QW at biologically active doses.
•Tumor reduction was observed across metastatic sites, including regression of 7 liver lesions in 4 patients (median −58%; range −16% to −100%).
•Patients treated with Q3W dosing continue to be followed; initial Q3W efficacy data are expected in Q2 2027.
Pharmacokinetics and Pharmacodynamics
•Exposure increased approximately dose-proportionally, and the pharmacokinetic profile supports evaluation of Q3W dosing.
•CTIM-76 demonstrated dose-dependent induction of IFN-γ and IL-2, with higher peak cytokine levels and CD69+ CD8 T cell activation observed in patients with tumor reduction, providing clinical pharmacodynamic evidence consistent with the proposed mechanism of target-dependent T cell activation.
Safety
•Cytokine release syndrome occurred in 5 of 27 patients (18.5%); all events were Grade 1 or 2.
•Grade ≥3 treatment-emergent adverse events occurred in 22 of 27 patients (81.5%) overall. The most common were increased gamma-glutamyl transferase (GGT; 37.0%), increased
aspartate aminotransferase (AST; 29.6%), increased alanine aminotransferase (ALT; 22.2%), increased lipase (18.5%), and anemia (14.8%).
•Grade ≥3 liver enzyme elevations were dose-related, occurring most frequently at 560 µg QW. At biologically active doses, Grade ≥3 AST and ALT elevations each occurred in 4 patients (21.1%). Hepatic enzyme elevations generally occurred early in treatment, were asymptomatic, and resolved with continued dosing.
Dose Escalation and Backfill
•The dose-limiting toxicity (“DLT”) evaluation period at 280 µg Q3W is complete (n=6 patients), and dose escalation to 420 µg Q3W (n=3–6) has begun. An additional 6 patients are being enrolled at 280 µg Q3W to further characterize that dose level.
Upcoming Expected Milestones:
•Q1 2027: Initiation of Phase 1b dose expansion
•Q2 2027: Phase 1a initial efficacy data with Q3W dosing in PROC patients
CT-202: Nectin-4 x CD3 TCE
Context is evaluating CT-202 as a monotherapy in a Phase 1 trial in patients with urothelial, colorectal and triple-negative breast cancers.
Recent Progress:
•September 2026: First patient dosed in Phase 1 trial
•Six sites are active in Australia
Upcoming Expected Milestones:
•2H 2027: Phase 1a initial data
•U.S. investigational new drug application filing on track by year-end 2026
Third Quarter 2026 Financial Results
•Cash and cash equivalents were $34.4 million at September 30, 2026, compared to $66.0 million at December 31, 2025. The Company expects its cash and cash equivalents will be sufficient to fund its operations to early fourth quarter of 2027.
•Research and development expenses were $5.7 million for the third quarter of 2026, compared to $8.7 million for the third quarter of 2025. The decrease was primarily driven by a $3.9 million reduction in CT-202 expenses, reflecting lower contract manufacturing and preclinical expenses. Higher CTIM-76, CT-95 and personnel-related costs partially offset this reduction.
•General and administrative expenses were $2.2 million for the third quarter of 2026, as compared to $1.9 million for the third quarter of 2025. The increase was primarily driven by higher salaries and personnel-related costs, including share-based compensation as compared to the same period in 2025.
•Other income was $0.3 million for the third quarter of 2026, as compared to $0.9 million for the third quarter of 2025, primarily due to lower interest income earned on cash and cash equivalent balances.
•Context reported a net loss of $7.6 million for the third quarter of 2026, as compared to $9.7 million for the third quarter of 2025.
References
1 Yu, J., Green, M.D., Li, S. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine 27, 152–164 (2021).
2 Cooper AJ, Sands J. T-cell engagers in small cell lung cancer. Cancer. 2026 Sep 15;132(18):e70600.
3 Sands J, et al. Tarlatamab plus durvalumab versus durvalumab alone in extensive-stage small-cell lung cancer: a phase 3 trial. New England Journal of Medicine. 2026;385(18):1623-1634.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia, PA. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, prospects, and plans and objectives of management, are forward-looking statements. These statements may be identified by words such as “may,” “will,” “expect,” “believe,” “could,” “estimate,” “potential,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions.
Forward-looking statements in this press release include, without limitation, statements regarding: (i) plans related to the Company’s research and development activities, and the expected timing and potential results thereof, including trial design and patient enrollment criteria, dose selection and escalation, Q3W dose optimization and the initiation of a Phase 1b dose expansion trial of CTIM-76; (ii) the potential for CTIM-76 to demonstrate improved efficacy or tolerability in less heavily pretreated patients and in Q3W dosing; (iii) the expected timing of clinical data for CTIM-76 and CT-202; (iv) the expected timing of regulatory filings; (v) the Company’s expectation regarding the sufficiency of its cash and cash equivalents; and (vi) other non-historical statements.
These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and the Company cannot assure that its plans, intentions, expectations, or strategies will be achieved. These risks and uncertainties include, without limitation: (i) uncertainties regarding the Company’s expectations, projections, and estimates of future costs and expenses, capital requirements, the availability of
additional financing and the Company’s capital requirements, including the Company’s ability to continue as a going concern; (ii) the timing, progress, and results of the Company’s discovery, preclinical and clinical development activities; (iii) clinical trial site activation and enrollment; (iv) unexpected safety or efficacy data observed during preclinical studies or clinical trials; (v) the risk that results from nonclinical or clinical studies may not be predictive of future results, and that interim data are subject to further analysis and may change as more patient data become available; (vi) uncertainties related to the regulatory approval process; (vii) the Company’s reliance on third parties; (viii) macroeconomic conditions; and (ix) whether the Company has sufficient funding to meet future operating expenses and capital expenditure requirements.
Additional factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and future reports.
Investor Relations Contact:
Jennifer Minai-Azary, Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com
Context Therapeutics Inc.
IR@contexttherapeutics.com
November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Important Notice and Disclaimers This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, prospects, and plans and objectives of management, are forward-looking statements. These statements may be identified by words such as “may,” “will,” “expect,” “believe,” “could,” “estimate,” “potential,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions. Forward-looking statements in this presentation include, without limitation, statements regarding (i) the Company’s business strategy, cash flows, cash runway and funding status, (ii) potential growth opportunities, (iii) clinical development activities, (iv) the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates, (v) estimates of potential market size and opportunity, and (vi) other non-historical statements. These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and the Company cannot assure that its plans, intentions, expectations, or strategies will be achieved. These risks and uncertainties include, without limitation: (i) uncertainties regarding the Company’s expectations, projections, and estimates of future costs and expenses, capital requirements, and the availability of additional financing, including the Company's ability to continue as a going concern; (ii) the timing, progress, and results of the Company’s discovery, preclinical and clinical development activities; (iii) clinical trial site activation and enrollment; (iv) unexpected safety or efficacy data observed during preclinical studies or clinical trials; (v) the risk that results from nonclinical or clinical studies may not be predictive of future results, and that interim data are subject to further analysis; (vi) uncertainties related to the regulatory approval process; (vii) the Company’s reliance on third parties; (viii) macroeconomic conditions; (ix) the potential for changes in the Company's strategy regarding its product candidates and clinical development activities; and (x) whether the Company has sufficient funding to meet future operating expenses and capital expenditure requirements. Additional factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including future reports. Except as required by law, the Company undertakes no obligation to update or revise any forward- looking statements, which speak only as of the date of this presentation, whether as a result of new information, future events or otherwise. Certain information contained in this presentation is based on studies, publications, surveys and other data obtained from third-party sources, as well as on the Company's own internal estimates and research. Although the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified the information obtained from such sources. In addition, all market data included in this presentation are subject to a number of assumptions and limitations. References in this presentation to research reports, articles or other publications should not be construed as a complete description of the findings of the referenced report, article or publication. This presentation discusses product candidates that are in preclinical and clinical development and that have not been approved for marketing by the U.S. Food and Drug Administration. The Company makes no representation as to the safety or effectiveness of any product candidate for the use for which it is being studied. Although the Company believes its internal research is reliable, such research has not been verified by any independent source. All scientific, preclinical and clinical data presented in this presentation are, by definition, preliminary in nature, as they precede the completion of the applicable clinical trial and the preparation of a clinical study report, and are subject to further quality-control procedures, including customary source data verification. The trademarks included in this presentation are the property of their respective owners and are used solely for reference purposes. Such use should not be construed as an endorsement of any such products. Forward-Looking Statements Executive Summary Context Therapeutics Inc. - November 20262
Executive Summary Pipeline Overview 3 PROGRAM TARGET LEAD INDICATION(S) PRECLINICAL PHASE 1 PHASE 2 ANTICIPATED MILESTONES CTIM-76 Claudin 6 Platinum-resistant ovarian cancer (PROC) Q1 2027: Initiate Phase 1b Q2 2027: Phase 1a initial Q3W dosing data CT-202 Nectin-4 Urothelial, colorectal, TNBC 2H 2027: Phase 1a initial data Fast Track Designation Context Therapeutics Inc. - November 2026 CTIM-76: Claudin 6 x CD3 CLDN6 is overexpressed in ovarian, endometrial, lung, testicular, and other solid tumors CTIM-76 was designed to bind selectively to CLDN6 over CLDN3, CLDN4, and CLDN9 CT-202: Nectin-4 x CD3 Nectin-4 is overexpressed in bladder, lung, breast, head and neck, and other solid tumors CT-202 was designed to be conditionally active within the tumor microenvironment and potentially allow a wider therapeutic window while sparing effects on normal tissue Our Strategy Target tumor antigens that are clinically validated by antibody drug conjugates (ADC) or chimeric antigen receptor T cell therapy (CAR-T) Focus on solid tumors with high unmet need Fast Track Designation for the treatment of platinum-resistant ovarian cancer (PROC) in patients who have exhausted all standard-of-care therapies
T Cell Engaging (TCE) Bispecific Antibodies Executive Summary Context Therapeutics Inc. - November 20264 Mechanism of Action T cell engagers are specialized medicines that help the body's own immune cells find and attack cancer. Each one works like a bridge: one end grabs onto a marker on the cancer cell, and the other end grabs onto a T cell, one of the immune system's main fighters. By pulling the two together, the T cell is switched on and can destroy the cancer cell. TCE-mediated Cancer Cell Death TCE Bispecific Antibody T Cell Cancer Cell Target Antigen CD3 Cancer Cell Killing
Context is Positioned to Develop the Next Generation of T Cell Engagers Potential to expand into early treatment lines through rational drug combinations Executive Summary Context Therapeutics Inc. - November 20265 Future Development Combination Approaches Near Term Development Optimized Novel Monotherapies CTIM-76 CT-202 Bispecific TCE Engineered for: Potential Opportunities for: • Antitumor activity • Reduced risk of CRS • Target selectivity • Clinically relevant exposure • Deeper and more durable responses • Advancement into earlier lines of therapy TCE + ADC TCE + PD-(L)1/VEGF + +
CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - November 20266
Our Initial Focus is on Platinum-resistant Ovarian Cancer (PROC) ~75% of PROC patients are CLDN6+ No approved treatment option specifically for this biomarker selected PROC population ~42,000 CLDN6+ PROC patients across United States, EU7, and Japan CLDN6 has significant target overlap with promising ADC targets, including B7H4, CDH6, FRα, and NaPi2b – opening the door to potential combination opportunities Additional opportunities in earlier lines of ovarian cancer and other tumor types with CLDN6 overexpression, including non-small cell lung (NSCLC) and endometrial cancer CTIM-76 Program Context Therapeutics Inc. - November 20267 Broad Use Case as Monotherapy or Combination Potential Opportunities for: • Monotherapy development post-ADC • Combination development with ADC, PD-(L)1/VEGF, or chemotherapy CTIM-76 + ADC + CTIM-76 Patient population based on multiplying NIH SEER 2026 ovarian cancer estimates in United States and prevalence estimates for EU7 and Japan by ~75% of all PROC (based on internal data) High unmet need for new therapies that can be used after or in combination with ADCs or PD-(L)1/VEGF therapies
CLDN6 is an Attractive Target for Immunotherapy • CLDN6 is an oncofetal protein: expressed during embryonic development, silenced or very low in normal adult tissue. • Expression increases with cancer disease stage • Tetraspan membrane protein with low internalization, favoring a TCE over an ADC, which relies on internalization to deliver its payload CTIM-76 Program Context Therapeutics Inc. - November 20268 Rationale for CLDN6 Targeting 1 Screnci, Cancer Res, 2022; 2 Tanaka, J Hepatol, 2018; 3 Cordat, Physiology, 2019; 4 Li, FEBS Open Bio, 2020 CLDN6 selectivity is required to avoid off-target liabilities The CLDN6 antibody binding region is highly conserved with CLDN3 and CLDN4 – differing by only 3 amino acids1 CLDN3 and CLDN4 are enriched in the liver and antibody binding may result in liver enzyme elevations2,3,4 CLDN3/4 Cross-reactivity is a Safety Consideration CLDN6 Protein Claudin Gene Family Extracellular Space Cytoplasm Antibody Binding Domain CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN18 CLDN11 CLDN15 CLDN10
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Designed to restrict T cell activation to CLDN6-expressing target cells • CLDN6-selective fragment antigen-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to avoid aberrant T cell activation • Silenced Fc domain to avoid off target immune cell activation Design features intended to improve tumor selectivity • T cell dependent cellular cytotoxicity with minimal activation of circulating cytokines Ease of manufacturing • IgG1 backbone is highly stable and enables high yield CTIM-76 Program Context Therapeutics Inc. - November 20269 α-CLDN6 Fab α-CD3 scFv IgG1 backbone Silenced Fc Optimized structure for CLDN6 selectivity, potency, and manufacturability
CTIM-76 Program CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody CTIM-76 CLDN6 EC50 of 3.41 nM (binding) CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 CLDN3/4/6/9 were transiently transfected in HEK-293F cells >10,000x Potency assay provides a physiologically-relevant assessment for a TCE bispecific more than binding assays for off-target liabilities associated with CLDN3/4/9 CTIM-76 CLDN6 EC50 of 0.4 pM (cytotoxicity) CTIM-76 preferentially targets CLDN6, with minimal binding and cytotoxicity against CLDN9-expressing cells CTIM-76 effectively engaged systemically administered human PBMC-engrafted mice to promote significant tumor regression and complete responses in OVCAR3 (~96,000 CLDN6 copies per cell) ovarian xenograft model CTIM-76 was well tolerated in OVCAR3 xenograft study NSG-b2m knockout mice (n=14/arm) engrafted with human PBMCs and bearing advanced subcutaneous OVCAR3 tumor xenografts were treated twice per week Context Therapeutics Inc. - November 202610 Selectivity Potency In Vivo Efficacy >500x Tumor Regression 0 150 300 450 600 0 7 14 21 Tu m or V ol um e (m m 3) Day Vehicle 0.01mg/kg 0.1mg/kg 1.0mg/kg
CTIM-76 Program CTIM-76 Phase 1 Study Design Context Therapeutics Inc. - November 202611 An open-label, multi-center, dose escalation / expansion, safety, and PK study Screening Phase 1a Dose Escalation (QW Dosing) Key Inclusion Criteria • CLDN6-positive by IHC (≥10% 1+ staining) • Age ≥18 years • Measurable disease per RECIST v1.1 • ECOG 0 or 1 Trial objectives • Assess safety and tolerability • Pharmacokinetic and pharmacodynamic data • Evaluate preliminary anti-tumor activity CRS Mitigation • Step / prime dose • Steroid prophylaxis during priming and first full dose 3+3 Design (Completed) 22.5 µg 70 µg 140 µg 210 µg 280 µg 560 µg 280 µg 420 µg Phase 1a Dose Escalation (Q3W Dosing) 3+3 Design & Backfill (Ongoing) Backfill Patients with platinum resistant ovarian cancer (PROC), endometrial, and testicular cancers Patients with PROC CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. 280 µg Q3W 420 µg Q3W 280 µg Q2W 280 µg Q3W OR Phase 1b Dose Expansion (Q1 2027) R 1:1 R 1:1
Phase 1a Clinical Data Observed with CTIM-76 CTIM-76 Program Context Therapeutics Inc. - November 202612 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. *RECIST-evaluable PROC population (n=9 patients at target doses) is defined as having measurable disease documented at baseline according to RECIST v1.1 criteria and at least one follow-up tumor assessment after a full cycle of treatment. Disease Control Rate: Patients achieving confirmed stable disease, partial response, or complete response. 1 2026 ESMO DeLLphi-305 Data as of October 30, 2026. Weekly Dosing (QW) QW PROC Experience* Every 3 weeks (Q3W) 22.5–560 µg QW Dose range evaluated with a single priming dose Heavily pretreated patients with ovarian, endometrial, or testicular cancer 22% ORR 56% DCR 5.6-month PFS Late-line PROC: median 7 prior therapies (range, 5–16) Evaluating ≥280 µg Q3W Completed: Dose escalation: 280 µg (n=6 patients) Currently enrolling: Dose escalation: 420 µg (n=3–6) Cohort backfill: 280 µg (n=6) Ovarian cancer focus Rationale: high prevalence of CLDN6 expression and unmet need following antibody–drug conjugate (ADC) therapy Biologically active doses Doses of 140 to 280 µg QW Q3W dosing strategy Intended to deepen responses by allowing T cells to recover between doses while keeping peak cytokine activation high Enroll earlier-line patients, who typically have lower tumor burden, more effector T cells, and better immune fitness1 Anti-tumor activity correlated with peak cytokine induction Manageable tolerability with limited low- grade cytokine release syndrome (CRS)
CTIM-76 Patient Demographics CTIM-76 evaluated in heavily pretreated patients with high tumor burden CTIM-76 Program Context Therapeutics Inc. - November 202613 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. All treated patients (≥1 dose). Age and ECOG at screening; prior therapies = number of prior anticancer regimens; Ovarian includes fallopian tube (n=1) and primary peritoneal (n=1). Sum of longest dimension = screening target lesions; liver metastases = liver target/non-target lesion at screening. H-score = CLDN6 IHC, latest biopsy. Baseline Characteristics All Patients Dose Levels 22.5–560 µg N 27 Age, median (range) 63 (29-76) ECOG, median (range) 0 (0-1) Ovarian, n (%) 20 (74.1) Testicular, n (%) 4 (14.8) Endometrial, n (%) 3 (11.1) Prior therapies, median (range) 6 (3-16) 1, n (%) 0 (0) 2 0 (0) 3 6 (22.2) 4 2 (7.4) ≥5 19 (70.4) Baseline Characteristics Ovarian (QW) Ovarian (Q3W) Dose Levels 140–280 µg 280 µg N 9 6 Age, median (range) 63 (53-72) 67 (43-76) ECOG, median (range) 1 (0-1) 0 (0-1) Sum of longest dimension (mm) 71 (39-114) 155 (28-205) Liver metastases, n (%) 4 (44) 4 (67) H-Score, median (range) 135 (25-300) 95 (20-150) Prior therapies, median (range) 7 (5-16) 6 (3-6) Checkpoint Inhibitor, n (%) 5 (56) 2 (33) ADC 8 (89) 4 (67) ≥ 2 ADC 3 (33) 2 (33) Topotecan 4 (44) 0 (0) DNA Repair: Chk1, PARP, Wee1 7 (78) 4 (67) VEGF or PD-1xVEGF 9 (100) 5 (83)
CTIM-76 Safety Summary CTIM-76 Program CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. Each patient is counted once per row. TEAE = treatment-emergent adverse event, meaning a side effect or health problem that started on or after the first day of treatment; related = related or possibly related to the study drug; dose delay / discontinuation = the patient's record shows the drug was delayed or paused ("Drug Delayed/Interrupted") or stopped ("Drug Withdrawn"); dose reduction = a lower dose was recorded on the dosing form. Biologically active dose cohorts = tumor reduction and T-cell cytokine induction with manageable safety. Dose Level 22.5 µg 70 µg 140 µg 210 µg 280 µg 280 µg 560 µg Total Schedule QW QW QW QW QW Q3W QW Patients N=1 N=3 N=4 N=5 N=4 N=6 N=4 N=27 Events n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) TEAE 1 (100.0) 3 (100.0) 4 (100.0) 5 (100.0) 4 (100.0) 5 (83.3) 4 (100.0) 26 (96.3) TEAEs Related to CTIM-76 1 (100.0) 2 (66.7) 4 (100.0) 5 (100.0) 4 (100.0) 5 (83.3) 4 (100.0) 25 (92.6) Serious TEAE 1 (100.0) 1 (33.3) 3 (75.0) 1 (20.0) 2 (50.0) 3 (50.0) 3 (75.0) 14 (51.9) Serious TEAEs Related to CTIM-76 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 2 (33.3) 3 (75.0) 7 (25.9) TEAE Leading to Dose Delay 0 (0.0) 0 (0.0) 2 (50.0) 3 (60.0) 2 (50.0) 1 (16.7) 4 (100.0) 12 (44.4) TEAE Leading to Dose Reduction 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0) 1 (3.7) TEAE Leading to Discontinuation 1 (100.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (25.0) 4 (14.8) Related TEAE Leading to Discontinuation 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (25.0) 2 (7.4) TEAEs of Special Interest 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 1 (25.0) 1 (16.7) 2 (50.0) 5 (18.5) CRS 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 1 (25.0) 1 (16.7) 2 (50.0) 5 (18.5) ICANS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Biologically Active Dose Cohorts (n=19) Context Therapeutics Inc. - November 202614 In biologically active dose cohorts, events were asymptomatic, transient and largely priming-related
Grade ≥ 3 Adverse Events by Dose Cohort In biologically active dose cohorts, events were asymptomatic, transient and largely priming-related CTIM-76 Program Dose Level 22.5 µg 70 µg 140 µg 210 µg 280 µg 280 µg 560 µg Total Schedule QW QW QW QW QW Q3W QW Patients N=1 N=3 N=4 N=5 N=4 N=6 N=4 N=27 Events n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) Any Adverse Event 1 (100.0) 1 (33.3) 4 (100.0) 5 (100.0) 3 (75.0) 4 (66.7) 4 (100.0) 22 (81.5) GGT increased 0 (0.0) 0 (0.0) 1 (25.0) 2 (40.0) 1 (25.0) 3 (50.0) 3 (75.0) 10 (37.0) AST increased 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 2 (50.0) 1 (16.7) 4 (100.0) 8 (29.6) ALT increased 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 2 (50.0) 1 (16.7) 2 (50.0) 6 (22.2) Lipase increased 0 (0.0) 0 (0.0) 0 (0.0) 2 (40.0) 0 (0.0) 3 (50.0) 0 (0.0) 5 (18.5) Anemia 0 (0.0) 1 (33.3) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 4 (14.8) ALP increased 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (25.0) 2 (7.4) Amylase increased 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0) 1 (16.7) 0 (0.0) 2 (7.4) Fatigue 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 2 (7.4) Pleural effusion 0 (0.0) 0 (0.0) 1 (25.0) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (7.4) Syncope 0 (0.0) 0 (0.0) 1 (25.0) 0 (0.0) 1 (25.0) 0 (0.0) 0 (0.0) 2 (7.4) CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. Grade ≥ 3 TEAEs by MedDRA preferred term, patients counted once per term. Biologically Active Dose Cohorts (n=19) Context Therapeutics Inc. - November 202615
CTIM-76 Program CTIM-76 Demonstrates a Manageable Safety Profile, With CRS Limited to Grade 1–2 16 Context Therapeutics Inc. - November 2026 CTIM-76-related TEAEs in ≥ 10% of patients Cytokine release syndrome by dose level 3 (11.1%) 3 (11.1%) 3 (11.1%) 3 (11.1%) 4 (14.8%) 4 (14.8%) 4 (14.8%) 4 (14.8%) 5 (18.5%) 5 (18.5%) 5 (18.5%) 6 (22.2%) 8 (29.6%) 9 (33.3%) 11 (40.7%) 12 (44.4%) 15 (55.6%) 0% 10% 20% 30% 40% 50% 60% 70% Pyrexia Blood bilirubin increased Back pain Anemia Weight decreased Lipase increased Headache Amylase increased Vomiting Cytokine release syndrome ALP increased Fatigue Pruritus Nausea ALT increased AST increased GGT increased Maximum grade: Grade 1 Grade 2 Grade 3 Grade 4 0/1 0/3 0/4 1/5 1/4 1/6 2/4 0% 20% 40% 60% 80% 100% 22.5 µg QW (n=1) 70 µg QW (n=3) 140 µg QW (n=4) 210 µg QW (n=5) 280 µg QW (n=4) 280 µg Q3W (n=6) 560 µg QW (n=4) Maximum grade: Grade 1 Grade 2 CRS in 5 of 27 patients (18.5%) • Grade 2 CRS in 1 patient at 560 µg QW; all other CRS grade 1 • CRS onset predominantly associated with first prime dose CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. TEAE = adverse event starting on or after the first CTIM-76 dose; related = related or possibly related to CTIM-76 (investigator). Patients counted once per term at their maximum grade; terms reported in ≥ 10% of all treated patients shown, % of n=27. Dose level = enrolled cohort (target dose; Q3W = Part 1a-B); CRS = MedDRA PT cytokine release syndrome, grade on the AE form. Data as of October 30, 2026.
Promising Antitumor Activity in QW Biologically Active Dose Cohorts Early efficacy signal in a heavily pretreated population supports advancing the QW biologically active doses Context Therapeutics Inc. - November 202617 Best Overall % Change in Tumor Size From Baseline* On treatment Other Endometrial or testicular cancer CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. RECIST-evaluable population (n=12 patients at biologically active doses, QW) is defined as having measurable disease documented at baseline according to RECIST v1.1 criteria and at least one follow-up tumor assessment after a full cycle of treatment. *Best tumor reduction at any time point in evaluable patients. Bars truncated at +20%. ▲ = best change >+20%. CRS = maximum grade on the AE form. CTIM-76 Program Dose-proportional cytokine release (Slide 23) with no severe CRS supports a manageable tolerability profile Tumor size reduction in 5 of 9 heavily pretreated PROC patients with QW dosing, including 2 confirmed partial responses (−73%, −43%) Sa fe ty Ef fic ac y Step Dose Cohort 70/140 µg QW 70/210 µg QW 140/280 µg QW -10% -15% -23% -37% -43% -73% -100% -80% -60% -40% -20% 0% 20% 0 1 2 3 4 OvarianOther Cytokine Release Syndrome (CRS) Grade ▲ ▲ ▲
Emerging Evidence of Durable Activity in QW Biologically Active Dose Cohorts CTIM-76 Program 18 CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. RECIST-evaluable population (n=12 patients at target doses, QW) is defined as having measurable disease documented at baseline according to RECIST v1.1 criteria and at least one follow-up tumor assessment after a full cycle of treatment. ORR = confirmed PR. Disease Control Rate: patients achieving confirmed stable disease, partial response, or complete response. Spider: % change in sum of target-lesion diameters at each complete re-assessment, by week from C1D1. Y axis shown from +20% to −100%; lines rising above +20% are truncated at the axis edge (▲). Context Therapeutics Inc. - November 2026 All Comers All Ovarian Ovarian QW Dosing 140 µg 210 µg 280 µg Patient enrolled, n 13 9 2 5 2 RECIST evaluable, n 12 9 2 5 2 Not RECIST evaluable, n 1 0 0 0 0 ORR, n (%) 2 (17) 2 (22) 1 (50) 0 (0) 1 (50) SD, n (%) 4 (33) 3 (33) 0 (0) 3 (60) 0 (0) DCR, n (%) 6 (50) 5 (56) 1 (50) 3 (60) 1 (50) Biologically Active Dose Range, Percent Change from Baseline (n=12) -100 -80 -60 -40 -20 0 20 0 4 8 12 16 20 24 28 32 36 40 44 48 52 C ha ng e fr om B as el in e (% ) Week 70/140 µg QW 70/210 µg QW 140/280 µg QW Step Dose Cohort On treatment
Greater T-Cell Activation With Tumor Reduction, Consistent With Target-Dependent Activity CTIM-76 Program Context Therapeutics Inc. - November 202619 Peak serum cytokines Activated CD8 T cells IFN-γ IL-2 CD69+ 10⁰ 10¹ 10² 10³ 10⁴ Reduction n=7 No Reduction n=11 *** Pe ak c on ce nt ra tio n, p g/ m L 10⁰ 10¹ 10² 10³ Reduction n=7 No Reduction n=11 * −5 0 +5 +10 +15 +20 +25 Reduction n=7 No Reduction n=11 * M ax c ha ng e, % p oi nt s Greater T cell activation in patients with tumor reduction • Higher median IFN-γ and IL-2 peaks in patients with best target-lesion change • Larger maximal increase from baseline in CD69+ frequency among CD8 T cells Support for mechanism of action • Biomarker evidence of T cell activation correlated with tumor reduction • Supports the proposed mechanism of CLDN6-directed T cell engagement CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Exploratory analysis as of October 30, 2026. Patients in QW cohorts with ≥1 sample of that biomarker ≥7 days after the first target dose at any visit. Mann–Whitney, unadjusted; whiskers 1.5× IQR. Cytokines: peak serum level. Open dot = below LLOQ. CD69+: highest change from C1D1 pre-dose, % of CD8 T cells. Reduction = best target-lesion change <0. Box = IQR · line = median · *p<0.05 ***p<0.001. LLOQ Tumor reduction associated with higher IFN-γ, IL-2 and CD69+ T cell responses Pe ak c on ce nt ra tio n, p g/ m L
CTIM-76 Program Duration of Treatment and Response in QW Biologically Active Dose Cohorts Context Therapeutics Inc. - November 202620 5.6 month median PFS (95% CI: 1.2-7.4 months) in late-line ovarian cancer CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. Swimmer plot includes all comers at Biologically Active Dose levels with QW dosing (n=13). Bar = C1D1 to end of treatment (ongoing: last recorded visit). Median PFS: Kaplan–Meier, ovarian QW (n=9); event = first RECIST 1.1 progression (incl. new lesion), censored at last assessment. * New lesion not found on subsequent scans. **Withdrew consent due to clinical progression before completing the DLT period. Indication Prior Rx Dose Schedule Ovarian 5 280 QW Ovarian 16 210 QW Ovarian 6 210 QW Ovarian 7 210 QW Ovarian 7 210 QW Ovarian 5 140 QW Ovarian 8 280 QW Ovarian 6 140 QW Ovarian 11 210 QW Testicular 3 280 QW Testicular 4 280 QW Endo 5 140 QW Testicular 3 140 QW 2 4 6 8 10 12 Time From Start of Treatment (months) ** Progressive Disease Stable Disease Partial Response RECIST Response New Lesion On treatment *
Treatment Duration With CTIM-76 vs Prior Therapy Time on CTIM-76 exceeded the most recent prior regimen in the majority of patients CTIM-76 Program Context Therapeutics Inc. - November 202621 CTIM-76 (140–280 µg QW)Prior Treatment CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. RECIST-evaluable patients at biologically active doses, QW (n=12); Prior Rx = most recent regimen before C1D1 (latest end date), start to end of regimen; CTIM-76 = C1D1 to end of treatment (ongoing: last visit). Prior Treatment Duration (months) 18 12 6 0 6 12 18 ACR-368 Etoposide Topotecan Gemcitabine + Denosumab Mirvetuximab VLS-1488 Etoposide Cyclophosphamide PTK7 ADC Ifosfamide + Paclitaxel + Cisplatin Etoposide Ivonescimab Ovarian Testicular Endometrial On treatment
CTIM-76 Program Decrease in Tumor Size Across Diverse Metastatic Sites, With Strong Responses in Liver Context Therapeutics Inc. - November 202622 Tumor size reduction by Location Target lesions with any decrease Liver Target Lesion Size Best % Change from Baseline Per Target Lesion CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026. All target lesions (n=30) in RECIST-evaluable ovarian patients at biologically active target doses, Best % change per lesion = lowest post-baseline measurement vs screening (lymph nodes: short axis); Reduction = any decrease. Lesions too small to measure were generally recorded as 5 mm; −100% = lesion no longer measurable (0 mm). Lesion-level changes are exploratory and are not RECIST overall response. Refs: 1. Hess KR, et al. Cancer. 2006;106:1624-1633. 2. Zhao H, et al. Front Oncol. 2020;10:571671. 3. Tian BW, et al. Clin Exp Metastasis. 2023;40:255-287. Liver 7 of 7 lesions Peritoneum / mesentery 5 of 14 lesions Lymph node 3 of 5 lesions Lung / pleura 1 of 2 lesions Vaginal cuff 0 of 2 lesions -58% -60% -16% -53% -57% -100% -100% -100% -80% -60% -40% -20% 0% 20% 70/140 µg QW 70/210 µg QW 140/280 µg QW Liver metastases are common and hard to treat with immunotherapy The liver is among the most frequent metastatic sites in solid tumors¹ and the most common distant site in ovarian cancer², and liver metastases predict shorter PFS and OS on checkpoint inhibitors³ 7 of 7 liver target lesions decreased across all 4 patients with liver mets (6 of 7 by ≥50%)
Cytokine Response Helps Inform Dose and Schedule Selection CTIM-76 Program Context Therapeutics Inc. - November 202623 Peak serum cytokine by Dose Level IFN-γ IL-2 10⁰ 10¹ 10² 10³ 10⁴ DL1 22.5/22.5 µg n=1 DL2 22.5/70 µg n=2 DL3 70/140 µg n=3 DL3a 70/210 µg n=5 DL4 140/280 µg n=4 DL5 140/560 µg n=3 Pe ak c on ce nt ra tio n, p g/ m L 10⁰ 10¹ 10² 10³ DL1 22.5/22.5 µg n=1 DL2 22.5/70 µg n=2 DL3 70/140 µg n=3 DL3a 70/210 µg n=5 DL4 140/280 µg n=4 DL5 140/560 µg n=3 Pe ak c on ce nt ra tio n, p g/ m L Response Rises With Dose • Cytokine release starts at 140 µg given weekly (QW) • Median IFN-γ and IL-2 peaks are highest at ≥280 µg QW Response Levels Off • No further increase in cytokine response is observed at 560 µg QW • This may reflect a QW schedule- dependent ceiling Actively exploring ≥280 µg with every 3 Weeks (Q3W) dosing • Longer dosing interval may allow greater T-cell recovery • Higher doses may help maintain effective exposure between doses • Q3W therefore provides an opportunity to explore greater and/or more sustained antitumor activity CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Exploratory analysis as of October 30, 2026. Peak = highest serum value from first dose through Day 37, measured ≥7 days after the first target dose. Whiskers 1.5× IQR. Box = IQR · line = median · open symbol = below LLOQ. LLOQ LLOQ Dose-dependent cytokine release consistent with T cell activation
CTIM-76 Program Cross-Trial Comparison of CTIM-76 and Other TCEs in PROC Context Therapeutics Inc. - November 202624 Encouraging tumor response, durability, and CRS rate Company Context Therapeutics Xencor Regeneron Immunocore Asset CTIM-76 XmAb541 Ubamatamab Brenetafusp Target CLDN6 CLDN6 MUC16 PRAME Prior ADC (%) 89 n.d. n.d. 11 Prior Lines, median 7 n.d. 4.5 5 PFS, median (months) 5.6 n.d. 3.0 3.3 ORR (%) 22 14 14 6 Reference 30 October 2026 Data Cut Q2 2026 Earnings Release ESMO 2022 ESMO 2024 Data are not from head-to-head studies. Cross-trial data interpretation should be considered with caution as it is limited by differences in study population, sample size, inclusion and exclusion criteria and many other factors. CTIM-76-101 ClinicalTrials.gov Identifier: NCT06515613. Data as of October 30, 2026.
CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - November 202625
Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapsed/Refractory (R/R) Setting CT-202 Program 26 Context Therapeutics Inc. - November 2026 Cancers Incidence (US Only) R/R Incidence Nectin-4 Positive Nectin-4 Med/High Patient Population Nectin-4-positive R/R Incidence Colon 158,850 36,600 39%1 9%1 14,274 Bladder (urothelial) 84,530 18,765 60%2 36%2 11,259 Breast (TNBC) 56,334 11,550 78%3 58%5 9,009 Non-Small Cell Lung 199,586 122,500 64%3 58%6 78,400 Pancreatic 67,530 47,850 71%3 37%3 33,974 Gastric 31,510 11,200 94%7 60%4 10,528 Esophageal 22,530 16,290 55%3 24%3 8,960 Head and Neck 72,680 12,000 59%3 18%3 7,080 Cervical 12,960 4,500 89%8 67%8 4,005 Initial indications of interest based on: • Nectin-4 prevalence • Patient population size • Target validation via antibody-drug conjugates (ADCs) Incidences based on public estimates; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; Patient population derived from Nectin-4 positive population multiplied by R/R incident population. 1 Context Internal Data; 2 Klumper, Clin Cancer Res, 2023; 3 Challita, Cancer Res, 2016; 4 Zhang, Oncol Lett, 2018; 5 Zeindler, Front Med, 2019; 6 Takano, Mol Bio, 2009; 7 Muro, ESMO Open, 2025; 8 Jian, 9MW2821 SGO 2024
CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - November 202627 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal keratinocytes, sweat glands, and hair follicles, Nectin-4 targeted treatments are associated with dermatological side effects • CT-202 uses pH dependent binding to both Nectin-4 and CD3 to minimize binding to healthy tissues and maximize binding and T cell activation within the tumor microenvironment • CT-202 incorporates pH-dependent binding to Nectin-4 and CD3, designed to favor activity in acidic tumor environments Preclinical tolerability and pharmacokinetics • Well tolerated at high dose in nonhuman primates • Pharmacokinetics may support Q2W or Q3W dosing Ease of manufacturing • IgG1 backbone is highly stable and enables high yield AACR 2026, “Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-Human development of CT-202”
CT-202 Program Clinical Precedent De-Risks pH-Dependent Binding for CT-202 Context Therapeutics Inc. - November 202628 Gotistobart and Ultomiris provide the strongest precedent for CT-202's design Gotistobart BNT316 / ONC-392 — anti-CTLA-4 Ultomiris® ravulizumab-cwvz — anti-C5 Challenge addressed • Systemic CTLA-4 blockade drives immune-related AEs, narrowing the therapeutic index • Frequent infusions; C5 antibody lost to target-mediated clearance pH-dependent design • Binds CTLA-4 in acidic tumor microenvironment; releases at neutral pH • Confines Treg depletion to the tumor • LS Fc mutations raise FcRn affinity at pH 6.0; release at pH 7.4 • pH-sensitive C5 release enables recycling Clinical & regulatory validation • Phase 3 Stage 1: median OS 18.5 vs 10.0 months; Grade ≥3 TRAEs 44.4% vs 48.8% • FDA Fast Track (2022); Orphan Drug (2026); Stage 2 ongoing • ~4x longer half-life than eculizumab; Q8W dosing • FDA-approved, marketed product PRESERVE-003 Stage 1 Gotistobart vs docetaxel, 2L+ sqNSCLC Median overall survival (months) 18.5 10.0 Gotistobart Docetaxel HR 0.572 43% lower risk of death vs docetaxel n=87 squamous pts (1:1); non-pivotal stage; no new safety signals PRESERVE-003 (NCT05671510) Stage 1; Source: BioNTech/OncoC4, IASLC WCLC 2026 (Sept 14, 2026). Gotistobart and Ultomiris are not Context programs; cross-trial comparisons are not head-to-head.
CT-202 is Designed to Optimize Tumor Selectivity and Minimize Off-tumor Toxicity CT-202 Program Context Therapeutics Inc. - November 202629 AACR 2026, “Targeting solid tumors with pH-dependent dual-specific TCEs: First-in Human development of CT-202” Minimize Activity in Normal Tissues at pH7.4 T cell activation at low pH(6.0) and normal pH(7.4) with OVCAR3 ovarian cancer cell targets CT-202 preferentially activated T cells at low pH, which should maximize potency in the TME and minimize on-target/off-tumor liabilities of a Nectin-4 directed therapeutic in normal tissues T cell Activation Assay Potency is Correlated With Target Density T cell activation by cells with varying levels of Nectin-4 CT-202 mediated robust T cell activation in the presence of the Nectin-4+ cells but not in the presence of the CHO-S cells lacking Nectin-4. Activation was proportional to the level of Nectin-4 on the surface of the target cells. T cell Activation Assay at Low pH(6.0) Preclinical Tolerability and Pharmacokinetics MTD was not identified and PK supports initial biweekly (Q2W) dosing No notable test-article related in-life effects at any dosage. HNSTD is the highest administered dosage of 25.0 mg/kg/dose Single dose PK following IV administration in NHP CT202-pH6.0 CT202-pH7.4 huIgG1-pH6.0 huIgG1-pH7.4 Log CT-202 (ng/mL) R LU Log CT-202 (ng/mL) Nectin-4 high Nectin-4 medium
CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - November 202630 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to an enfortumab TCE control antibody Lower Cytokine Induction CT-202 treatment resulted in significantly lower IL-6 induction compared to a non-conditional enfortumab TCE benchmark in NHP C T- 20 2 En fo rt um ab T CE C T- 20 2 En fo rt um ab T CE Control CT-202 1 mg/kg CT-202 0.5 mg/kg CT-202 0.25 mg/kg Control Enfortumab TCE 1 mg/kg Enfortumab TCE 0.5 mg/kg Enfortumab TCE 0.25 mg/kg pH conditional Not pH conditional CT-202 0.1 mg/kg CT-202 1 mg/kg CT-202 5 mg/kg Enfortumab TCE 0.1 mg/kg Enfortumab TCE 1 mg/kg Enfortumab TCE 5 mg/kg 30x Higher
CT-202 Phase 1 Study Design An open-label, multi-center, dose escalation / expansion, safety, and PK study 31 CT-202 Program Context Therapeutics Inc. - November 2026 Screening Phase 1a Dose Escalation (Q2W Dosing) Key Inclusion Criteria • Patients with advanced metastatic urothelial, colorectal, and triple negative breast cancers • Age ≥18 years • Measurable disease per RECIST v1.1 • ECOG 0 or 1 Biomarker Stratification • Nectin-4 positive (≥10% of cells 1+ IHC) CRS Mitigation • Step / prime dose • Steroid prophylaxis on W1D1 and W2D8 Bayesian Optimal Interval (BOIN) Design & Backfill 18 µg 36 µg 72 µg 120 µg 180 µg Backfill ≥1 dose levels meeting protocol-defined safety and activity criteria Potential Backfill Potential Backfill Potential Backfill CT202-101 ClinicalTrials.gov Identifier: NCT07545122. Data as of October 30, 2026. Potential Backfill Study Update • 6 trial sites open in Australia • Cohort 1 is ongoing • US IND filing by YE 2026
Selected Nectin-4-directed Immune-engaging Programs Programs differ in molecular format, immune effector, and conditional-activation strategy CT-202 Program Context Therapeutics Inc. - November 202632 Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Marengo Therapeutics LabGenius Asset CT-202 BT74801,2 RNDO-5643 TriSTAR07014 LGTX-1015 Format 2 + 2 (pH dependent) 1 + 2 (Bicycle) 1 + 1 (Fixed light chain) 1 + 1 (+wt IL2) 3 + 1 Conditionally active ✘ ✘ ✘ ✘ Avidity enhanced ✘ ✘ ✘ Immune Effector CD3 4-1BB CD28 CD3 CD3 Program Status Phase 1 (FPI September 2026) Phase 1 (completed) Phase 1 (FPI Dec 2025) Preclinical Preclinical 1 Bicycle Therapeutics Corp Presentation 2024; 2 Hurov, J Immunother Cancer, 2021; 3 PEGS Boston 2024 ; 4 SITC 2025; 5 ESMO 2026. Information provided in the table above is for illustrative purposes only and is not a head-to-head comparison. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies.
Corporate 33 Context Therapeut ics Inc . - November 2026
Corporate Experienced management team Clinical team has developed T cell therapies Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD Chief Medical Officer Context Therapeutics Inc. - November 202634 Jennifer Dashnau, PhD SVP Technical Operations Jennifer Minai Chief Financial Officer Experienced Leadership Team Jill Conwell, MBA Consulting Chief People Officer
Corporate Investment Highlights (Nasdaq: CNTX) Context Therapeutics Inc. - November 202635 Investment Rationale Anticipated Milestones Large Unmet Need Solid tumors and ADC resistance High-Value Targets Claudin 6 and Nectin-4 Strong Team Deep oncology experience Focus on clinical execution Q2 2027 CTIM-76 Phase 1a initial Q3W data 2H 2027 CT-202 Phase 1a initial data Expected cash runway to early Q4 2027
c o n t ex t © CONTEXT THERAPEUTICS 2026 context t h e r a p e u t i c s Advancing T Cell Engagers for Solid Tumors Co text Therapeut ics Inc . - November 202636
Glossary Appendix MTD Maximum tolerated dose N.D. Not disclosed ORR Objective response rate PFS Progression-free survival PK Pharmacokinetic PR Partial Response PROC Platinum-resistant ovarian cancer QW Every week Q3W Every three weeks scFv Single-chain variable fragment SD Stable Disease TCE T cell engager TNBC Triple-negative breast cancer YE Year End Context Therapeutics Inc. - November 202637 ADC Antibody drug conjugate AE Adverse event CAR-T Chimeric antigen receptor T cell therapy CD3 Cluster of differentiation 3 CLDN Claudin CRS Cytokine release syndrome DLT Dose limiting toxicity Fab Fragment antigen-binding FIH First-in-human FPI First Patient In (dosed) FRα Folate receptor alpha GPI Glycosylphosphatidylinositol IHC Immunohistochemistry IND Investigational new drug IV Intravenous LLOQ Lower limit of quantitation MABEL Minimum anticipated biologic effect level MoA Mechanism of action